Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer

GME751 (pembrolizumab biosimilar) - Sandoz

Padcev (enfortumab vedotin-ejfv) - Astellas, Pfizer

quemliclustat (AB680) - Arcus Biosciences, Gilead

Arfleyda (pembrolizumab biosimilar) - R-Pharm

QL2107 (pembrolizumab biosimilar) - Qilu Pharma, Cipla, Orion Corp

Keytruda (pembrolizumab) - Merck (MSD)

Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer (clinicaltrials.gov) - Sep 18, 2026 - P1/2 | N=27 | Recruiting | Sponsor: Fred Hutchinson Cancer Center | Not yet recruiting ➔ Recruiting
Enrollment open • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

http://clinicaltrials.gov/ct2/show/NCT07667335

Sep 18, 2026